Systemic Side Effects of COVID-19 Vaccine Tied to Greater nAB Response
By Elana Gotkine HealthDay Reporter
TUESDAY, June 11, 2024 -- Short-term systemic side effects of the severe acute respiratory coronavirus 2 (SARS-CoV-2) mRNA vaccine are associated with greater long-lasting neutralizing antibody (nAB) responses, according to a study published online June 11 in the Annals of Internal Medicine.
Ethan G. Dutcher, M.D., Ph.D., from the University of California, San Francisco, and colleagues conducted a prospective cohort study in the San Francisco Bay Area to examine whether short-term side effects of SARS-CoV-2 mRNA vaccination are associated with subsequent nAB response. A total of 363 adults who had not been vaccinated against or exposed to SARS-CoV-2 and then received two doses of BNT162b2 or mRNA-1273 were included in the symptom-related analyses.
The researchers observed associations for chills, tiredness, feeling unwell, and headache with 1.4- to 1.6-fold higher nAB at one and six months, respectively, after vaccination. Across both follow-up time points, symptom count and vaccination-induced change in skin temperature and heart rate were positively associated with nAB. Each 1-degree Celsius increase in skin temperature after vaccination dose 2 was associated with 1.8- and 3.1-fold higher nAB one and six months later, respectively.
"These data may help to address the low rate of ongoing vaccine uptake, given that this seems to be at least partly the result of worry about side effects," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted June 2024
Further Support and Information on COVID-19
Read this next
COVID-19 Vaccination Not Tied to Adverse Pregnancy Outcomes
TUESDAY, June 25, 2024 -- mRNA COVID-19 vaccination during pregnancy is not associated with an increased risk of adverse pregnancy outcomes, according to a study published in the...
Cannabis Use Tied to Risk of COVID-19 Hospitalizations, ICU Admissions
TUESDAY, June 25, 2024 -- Current cannabis use may be an independent risk factor for COVID-19–related complications, according to a study published online June 21...
FDA Approves Capvaxive Pneumococcal 21-Valent Conjugate Vaccine
FRIDAY, June 21, 2024 -- The U.S. Food and Drug Administration has approved the Capvaxive pneumococcal 21-valent conjugate vaccine for the prevention of invasive pneumococcal...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.